Editas Medicine advances gene-editing drug EDIT-401 with strong preclinical results, targeting human trials by end of 2026

Editas Medicine reported positive first-quarter 2026 results, highlighting progress on EDIT-401, a gene-editing therapy aimed at treating hyperlipidemia by significantly reducing LDL cholesterol and other cardiovascular risk factors in preclinical studies. The company plans to start first-in-human trials for EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia later this year, with early proof-of-concept data expected by year-end 2026. Financially, Editas reduced its net loss compared to the previous year and maintains sufficient cash to fund operations into late 2027. The company also confirmed a favorable patent decision supporting its CRISPR technology rights. Upcoming presentations will share new preclinical data at major scientific conferences.